Skip to main content

Market Overview

UPDATE: Barclays Capital Initiates Coverage On Vertex Pharmaceuticals On Leading Position In CF Market


In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) with an Equal-Weight rating and $120.00 price target.

In the report, Barclays Capital noted, “Vertex's leading position in the CF market should be further augmented in 2015 with the launch of the Kalydeco/VX-809 combo in patients homozygous for the F508del mutation. That said, we think that it will take time for seamless reimbursement and broad access to be established in the US / EU. As a result, we're modestly ahead of consensus on 2015 combo sales (~$75M) but meaningfully ahead on 2016 sales (~$230M). In the pipeline, the 1H15 launch of a broad Kalydeco/VX-661 phase 3 program could further expand Vertex's reach in CF, but data release is likely a 2016 event. Overall, we're very impressed with Vertex's CF franchise, but we think that both pipeline catalysts and upside potential in CF are weighted more to 2016, not 2015. Hence, we're initiating coverage with an Equal Weight and $120 price target.”

Vertex Pharmaceuticals closed on Monday at $121.03.

Latest Ratings for VRTX

Apr 2021Morgan StanleyMaintainsEqual-Weight
Feb 2021BairdUpgradesNeutralOutperform
Feb 2021Piper SandlerMaintainsOverweight

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings


Related Articles (VRTX)

View Comments and Join the Discussion!

Posted-In: Barclays Capital Geoffrey MeachamAnalyst Color Initiation Analyst Ratings

Latest Ratings

SELFAegis CapitalInitiates Coverage On6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at